This article, second in a two-part review, discusses investigational drug therapy and miscellaneous drug management of parkinsonism. Drug therapy should be individualized according to signs and changed as the disease progresses or if the patient develops intolerable side effects. Investigational drugs being examined include sustained-release and injectable dopaminergic formulations. Drug-induced parkinsonism is also examined.
GoldsteinMLeibermanALewJ. The interactions of pergolide with central dopaminergic receptors. Proc Natl Acad Sci USA1980; 77: 3725–28.
2.
LewittpWardcNtLarse. Comparison of pergolide and bromocriptine therapy in parkinsonism. Neurology1983; 33: 1009–14.
3.
DuVoisin RHeikkilaRManzinoL. Pergolide-induced circling in rats with 6-hydroxydopamine lesions in the nitrostriatal pathway. Neurology1983; 33: 1387–91.
4.
KleinbergDLiebermanAToddJGreis1NgJNeophytidesA KUPERSMITH M. Pergolide mesylate: a potent day-long inhibitor of prolactin in rhesus monkeys and patients with Parkinson's disease. J Clin Endocrinol Metab1980; 57: 152–4.
5.
LiebermanANeophytidesA. Leibowitz M. Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease. Adv Neurol1983; 37: 95–108.
6.
LiebermanAGoldsteinMLeibowitzM. Treatment of advanced Parkinson disease with pergolide. Neurology1981; 37: 675–82.
7.
TannerCGoetzCGlantzRGlattSlKlawansHl. Pergolide mesylate and idiopathic Parkinson disease. Neurology1982; 32: 1175–9.
8.
LiebermanAGoldsteinMGopinathanG. Further studies in Parkinson disease. Neurology1982; 32: 1181–4.
9.
LangAQuinnNBrincatSMarsdenCdParkesJd. Pergolide in late-stage Parkinson disease. Ann Neurol1982; 72: 243–7.
10.
IlsonJFahnSMayeuxRCoteLjSniderSr. Pergolide treatment in parkinsonism. Adv Neurol1983; 37: 85–94.
11.
QuinnNLangAThompsonCBrincatSMarsdenCdParkesJd. Pergolide in the treatment of Parkinson's disease. Adv Neurol1984; 40: 509–13.
12.
LangASheehyMQuinnNBrincatSMarsdenCParkesJd. Lisuride and pergolide in Parkinson's disease. Adv Neuro!1983; 37: 109–20.
13.
LiebowitzMLiebermanANeophytidesA. Gopinathan GGoldsteinM. The effects of pergolide on the cardiovascular system of 40 patients with Parkinson's disease. Adv Neurol1983; 37: 121–30.
14.
LiebermanAGoldsteinMNeophytidesA. The use of pergolide, a potent dopamine agonist, in Parkinson's disease. Clin Pharmacol Ther1982; 32: 70–5.
15.
TannerCKlawansH. Pergolide mesylate: new therapy for Parkinson disease. Ann Intern Med1982; 96: 522–3.
16.
JankovicJ. Controlled trial of pergolide mesylate in Parkinson's disease and progressive supranuclear palsy. Neurology1983; 33: 505–7.
17.
JankovicJ. Treatment of Parkinson disease and progressive supranuclear palsy: a controlled trial of pergolide mesylate (letter). Neurology1982; 32: A182.
18.
QuinnNTooneBLangAMarsdenCdParkesJd. Dopa dose-dependent sexual deviation. Br J Psychiatry1983; 742: 296–8.
19.
KlawansHTannerCGlattSGoetzCg. A 6-mOnth trial of pergolide mesylate in the treatment of Parkinson's disease. Adv Neurol1983; 37: 75–83.
20.
LiebermanAGoldsteinMLeibowitzM. Long-term treatment with pergolide: decreased efficacy with time. Neurology1984; 34: 223–6.
21.
AgnoliARuggieriSBaldassarreMStocchiFDenaroAFalaschiP. Dopinergic ergots in parkinsonism. In: CaineD, McDonaldR, HorowskiR, WuttkeW, eds. Lisuride and other dopamine agonists. New York: Raven Press, 1983:407–17.
22.
LewittPGopinathanGWardC. Lisuride versus bromocriptine treatment in Parkinson disease: a double-blind study. Neurology1982; 32: 69–72.
23.
SchachterMSheehyMParkesJMarsdenCd. Lisuride in the treatment of parkinsonism. Acta Neurol Scand1980; 62: 382–5.
24.
LiebermanAGopinathanGNeophytidesALeibowitzMWalkerRHiesigerE. Bromocriptine and lisuride in Parkinson disease. Ann Neurol1983; 73: 44–7.
25.
CaraceniTGiovannin1PParatiESciglianoGGrassiMpBromocriptineCarella F. and lisuride in Parkinson's disease. Adv Neurol1984; 40: 531–5.
26.
GopinathanGTeravainenHDambrosiaJ. Lisuride in parkinsonism. Neurology1981; 37: 371–6.
27.
RinneU. New ergot derivatives in the treatment of Parkinson's disease. In: CalneD, McDonaldR, HorowskiR, WuttkeW, eds. Lisuride and other dopamine agonists.New York: Raven Press, 1983:431–42.
28.
LiebermanAGoldsteinMNeophytidesA. Use of lisuride in advanced Parkinson's disease. Potent dopamine and serotonin agonists. NYState J Med1981; 57: 1751–5.
29.
UlmG. Experiences with lisuride in the treatment of Parkinson's disease. In: CalneD, McDonaldR, HorowskiR, WuttkeW, eds. Lisuride and other dopamine agonists.New York: Raven Press, 1983:463–72.
30.
LeesASternG. Pergolide and lisuride for L-dopa-induced oscillations (letter). Lancet1981 ; 2: 577.
31.
LiebermanAGopinathanGNeophytidesALeibowitzMGoldsteinM. Pergolide and lisuride in advanced Parkinson's disease. Adv Neurol1984; 40: 503–7.
32.
ParkesJSchachterMMarsdenCSmithBWilsonA. Lisuride in parkinsonism. Ann Neurol1981; 9: 48–52.
33.
RiedererPJellingerKDanielczykW. Combination treatment with selective monoamine oxidase inhibitors and dopaminergic agonists in Parkinson's disease: biochemical and clinical observations. Adv Neurol1983; 37: 159–76.
34.
LiebermanaGoldstein MNeophytidesA. Lisuride in Parkinson disease: efficacy of lisuride compared to L-dopa. Neurology1981; 37: 961–5.
35.
LiebermanaGoldstein MLeibowitzM. Lisuride combined with L-dopa in advanced Parkinson disease. Neurology1981; 37: 1466–9.
36.
LiebermanAGoldsteinMGopinathanG. Further studies with lisuride in Parkinson's disease. Eur Neurol1983; 22: 119–23.
37.
McdonaldRHorowskiR. Lisuride in the treatment of parkinsonism. Eur Neurol1983; 22: 240–55.
38.
QuinnNMarsdenCSchachterMThompsonCLangAeParkesJd. Intravenous lisuride in extra-pyramidal disorders. In: CalneD, McDonaldR, HorowskiR, WattkeW, eds. Lisuride and other dopamine agonists.New York: Raven Press, 1983:383–93.
39.
SuchyIHorowskiR. Use of ergot derivative lisuride in Parkinson's disease. Adv Neurol1984; 40: 515–21.
40.
KellerHhDapradaM. Central dopamine agonistic activity and microsomal biotransformation of lisuride, lergotrile and bromocriptine. Life Sci1979; 24: 1211–22.
41.
SerbyMAngristBLiebermanA. Psychiatric effects of bromocriptine and lergotrile in parkinsonian patients. Adv Bio-chem Psychopharmacol1980; 23: 287–92.
42.
TeychennePZieglerMLakeCEnnaS. Low CSF-GABA in parkinsonian patients who respond poorly to therapy or suffer from the “on-off” phenomenon. Ann Neurol1982; 77: 76–9.
43.
BellRCarruthARosenbergRBoyarRm. Effect of dopamine agonist (lergotrile mesylate) therapy on twenty-four hours secretion of prolactin in treated Parkinson's disease. J Clin Endocrinol Metab1978; 47: 807–11.
44.
LiebermanAnGopinathanGEsteyEKupersmithMGoldsteinM. Further studies with lergotrile in Parkinson's disease (abstract). Neurology1978; 25: 343.
45.
DourishC. Piribedil: behavioral, neurochemical and clinical profile of a dopamine agonist. Prog Neuropsychopharmacol Biol Psychiatry1983; 7: 3–27.
46.
CannonJgDemopoulosBjLongJRFlynnJRSharabiFm. Proposed dopaminergic pharmacophore of lergotrile, pergolide, and related ergot alkaloid derivatives. J Med Chem1981; 74: 238–40.
47.
AcidYPollakPBonnetAmSignaretJlLhermitteF. Bromocriptine associated with a peripheral dopamine blocking agent in treatment of Parkinson's disease. Lancet1979; 7: 570–2.
48.
BaldessariniRj. Drugs and the treatment of psychiatric disorders. In: GilmanAGGoodmanLSRallTWMuradF eds. Goodman and Gilman's the pharmacological basis of therapeutics. New York: Macmillan, 1985:387–445.
49.
LewinR. Brain enzyme is the target of drug toxin. Science1984; 225: 1460–2.
50.
BurnsRsLewittPaEbertMhPakkenbergAKopinI. The clinical syndrome of striatal dopamine deficiency: parkinsonism induced by l-methyl-4-phenyl-l, 23, 6-tetrahydropyride(MPTP). N Engl J Med1985; 372: 1418–21.
51.
BallardPaTetrudJwLangstonJw. Permanent human parkinsonism due to l-methyl-4-phenyl 12, 3, 6-tetrahydropyridine (MPTP): seven cases. Neurology1985; 35: 949–56.
52.
LangstonJwBallardPTetrudJwIrwinI. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science1983; 279: 979–80.
RamsdenDbWilliamsAc. Production in nature of compound resembling methyl phenyl tetrahydropyridine, a possible cause of Parkinson's disease. Lancet1985; 7: 215–6.
LangstonJwBallardPa. Parkinson's disease in a chemist working with l-methyl-4-phenyl-l, 23, 6-tetrahydropyridine (letter). N Engl J Med1983; 309: 310.
57.
LewinR. Parkinson's disease: an environmental cause?Science1985; 229: 257–8.
58.
NuttJgRobinAjEislerTCalneDbChaseTn. Effect of an opiate antagonist on movement disorders. Arch Neurol1978; 35: 810–1.
59.
VardiJFlechterSRegevI. The modulatory effect of opiate receptor inhibitor in parkinsonism. Curr Ther Res1979; 26: 1015–8.
60.
LohHhBraseDaSompath-KhannaSMarJbWayElLiCh. ß-Endorphin in vitro inhibition of striatal dopamine release (letter). Nature1976; 264: 567.
61.
CollinsGsSandlerMWilliamsEdYoudimMbh. Multiple forms of human brain mitochondrial monoamine oxidase. Nature1970; 225: 817–20.
62.
BirkmayerWRiedererPYoudimMbhLinauerW. The potentiation of the anti akinetic effect by an inhibitor of MAO-B, deprenil. J Neurol Trans1975; 36: 303–26.
63.
CalneDb. Developments in the pharmacology and therapeutics of parkinsonism (current review). Ann Neurol1977; 7: 111–9.
64.
StrieflerMVardiJBorensteinNRabeyMjFlechterS. Beta-type mono-amine oxidase (MAO) inhibitors in long-term L-dopa-treated parkinsonism: a combined clinical trial with L-deprenyl. Curr Ther Res1980; 27: 643–8.
65.
ReynoldsGpElsworthTdBlauKSandlerMLeeAjSternGm. Deprenyl is metabolized to methamphetamine and amphetamine in man (letter). Br J Clin Pharmacol1978; 6: 542–4.
66.
TyrerPj. Use of ß-blocking drugs in psychiatry and neurology. Drugs1980; 20: 300–8.
67.
VASCJ. Propranolol in parkinsonian tremor. Lancet1966; 7: 182–3.
68.
LehmannJ. Tryptophan malabsorption in L-dopa-treated parkinsonian patients. Acta Med Scand1973; 794: 181–9.
69.
FahnSSniderSPrasadAlLaneEMakadonH. Normalization of brain serotonin in L-dopa-treated rats by L-tryptophan. Neurology1975; 25: 861–5.
70.
BryantRc. Duration of illness and response to tryptophan in Parkinson's disease (letter). Arch Neurol1980; 37: 677.
71.
BeasleyBlNuttJgDavenportRwChaseTn. Treatment with tryptophan of L-dopa-associated psychiatric disturbances. Arch Neurol1980; 37: 155–6.
72.
MurphyDl. Amine precursors, amines, and false neurotransmitters in depressed patients. Am J Psychiatry1972:7.29:141–8.
73.
BorisonRlDiamondBiBauerMlRajanKs. A new system for L-dopa delivery to brain (abstract). Neurology1980; 30: 365.
